Attorney General Josh Stein has worked across state and party lines to hold corporations accountable for their role in creating and fueling the opioid epidemic.  These efforts are bringing hundreds of millions of dollars to North Carolina communities to support treatment, recovery, harm reduction, and other life-saving programs and services.

In July 2021, Attorney General Stein announced a historic $26 billion national agreement with the three largest drug distributors plus the drug maker Johnson & Johnson (J&J), an agreement that will bring as much as $750 million to North Carolina communities to address the opioid epidemic. In September he called on local governments to join these national agreements to maximize resources flowing to North Carolina. Learn more.

Earlier in the year, Attorney General Stein and the NC Association of County Commissioners unveiled a Memorandum of Agreement (NC MOA) governing how North Carolina will use the proceeds of the $26 billion distributor/J&J settlements as well as proceeds from the Purdue and Mallinckrodt bankruptcy proceedings.  More than 80 local governments have joined the NC MOA as of September 2021, with more coming on board every week. Learn more.

More than three years ago, Attorney General Stein sued drug maker Purdue Pharma over deceptive marketing practices that created and fueled the opioid epidemic.  In July 2021, after years of negotiation, Attorney General Stein announced his support for confirmation of a bankruptcy plan for Purdue Pharma that will make billions of dollars available nationwide to fund efforts to remediate the opioid crisis.  This includes an estimated $100 million coming to North Carolina communities to support treatment, recovery, harm reduction, and other life-saving programs and services. Learn more.

In February 2021, Attorney General Stein announced a $573 million multi-state settlement with one of the world’s largest consulting firms, McKinsey & Company – including nearly $19 million for North Carolina.  The settlement resolves investigations into the company’s role in advising opioid companies on how to promote their drugs and profit from the opioid epidemic. Learn more.